Multi-country

One in Eight Cancers Starts With an Infection

Survodutide’s Phase III data raise a bigger question than weight loss

ESR1 Resistance Is Becoming a Treatment Pathway, Not a Footnote

AMR Plans Without Money

Life insurers are moving from pricing metabolic risk to trying to reduce it

CLL Just Moved a Noncovalent BTK Inhibitor Into First Line

Europe wants to catch cardiovascular risk before the first event

The Pandemic Deal Has A Hole.

As GLP-1 use scales, dermatology is becoming part of obesity care
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
